Citations

Citations to this article as recorded by  

• Engineered exosomal delivery of semaglutide activates SIRT1–FOXO3a–miR-124 signaling and protects against cortical neuroinflammation
  Elsayed A. Elmorsy, Sameh Saber, Ahmed Y. Kira, Manal Mohamed Hatem, Mohammed Alorini, Suzan Awad AbdelGhany Morsy, Hamad Alsaykhan, Abdulaziz A. Alsalloom, Nahla B. Mohamed, Norah Suliman Alsoqih, Rabab S. Hamad, Youssef El-Sayed, Nagwa Mahmoud Ramadan,
  Journal of Drug Delivery Science and Technology.2026; : 108078.     CrossRef
• Gastrointestinal Adverse Effects of GLP-1 and Dual GLP-1/GIP Receptor Agonists: A Comprehensive Update in Diabetic and Obese Populations
  Nimet Yılmaz, Mehmet Bastemir
  Diabetes, Metabolic Syndrome and Obesity.2026; Volume 19: 1.     CrossRef
• Glucagon-Like Peptide-1 Receptor Agonists and Acute Pancreatitis: Current Evidence and Clinical Implications
  Kwang Hyun Chung, Jaihwan Kim
  The Korean Journal of Pancreas and Biliary Tract.2026; 31(1): 1.     CrossRef
• Response to comment on “Efficacy and safety of GLP-1 receptor agonists in the management of obstructive sleep apnea in individuals without diabetes: A systematic review and meta-analysis of randomized, placebo-controlled trials”
  Chia Siang Kow, Dinesh Sangarran Ramachandram, Syed Shahzad Hasan, Kaeshaelya Thiruchelvam
  Sleep Medicine.2025; 134: 106709.     CrossRef
• Emerging Frontiers in GLP-1 Therapeutics: A Comprehensive Evidence Base (2025)
  Shikha Patel, Sarfaraz K. Niazi
  Pharmaceutics.2025; 17(8): 1036.     CrossRef
• GLP-1 Receptor Agonists in Mood Disorders: A Psychiatric Perspective
  Pietro Carmellini, Alessandro Cuomo, Maria Beatrice Rescalli, Andrea Fagiolini
  Life.2025; 15(9): 1422.     CrossRef
• Development of a risk prediction model for gastrointestinal adverse events associated with semaglutide administration in patients with type 2 diabetes mellitus
  Deyong Yue, Xuesheng Hua, Ling Zhu, Jun Wang, Lihua Gu, Zhengxia Yuan, Wenle Jian, Yirong Chen, Guoliang Meng
  Frontiers in Endocrinology.2025;[Epub]     CrossRef
• Bridging Efficacy and Adherence in Glucagon-Like Peptide-1 Receptor Agonist Therapy: The Emerging Role of Oral Agents
  Sherry Yun Wang, Ryan Stofer, Hao Wang, Gregory A. Brent, Lu Shi, Yu Cai, Moom Roosan, Tannaz Moin
  Diabetes & Metabolism Journal.2025; 49(6): 1331.     CrossRef
• Semaglutide from Bench to Bedside: The Experimental Journey Towards a Transformative Therapy for Diabetes, Obesity and Metabolic Liver Disorders
  Ralf Weiskirchen, Amedeo Lonardo
  Medical Sciences.2025; 13(4): 265.     CrossRef
• Seizure recurrence after GLP‐1 receptor agonist initiation in adults with epilepsy
  Majd A. AbuAlrob, Abdullah Hussein, Rand Abdellatif, Adham Itbaisha, Khaled Zammar, Boulenouar Mesraoua
  Epilepsia.2025;[Epub]     CrossRef
• Nutrient-Stimulated Hormone-Based Therapies: Transforming Obesity Management
  Ki Hoon Kwak, Chang Hee Jung
  Endocrinology and Metabolism.2025; 40(6): 879.     CrossRef
• Research Progress of GLP-1 Receptor Agonists in the Treatment of Alzheimer’s Disease
  琳娜 勾
  Advances in Clinical Medicine.2025; 15(12): 2047.     CrossRef

Citations

Citations to this article as recorded by  

• Trends in nephrology: kidney metabolism as a therapeutic target
  Jessica S Kleer, Markus M Rinschen
  Nephrology Dialysis Transplantation.2026; 41(2): 193.     CrossRef
• Age disparities in SGLT2 inhibitor prescription among people with type 2 diabetes: The role of frailty and sex
  Changyuan Yang, Petra Denig, Lynne Chepulis, Ryan G. Paul, Jung‐Im Shin, Ron T. Gansevoort, Priya Vart
  Diabetes, Obesity and Metabolism.2026;[Epub]     CrossRef
• Diabetic kidney disease: integrating multi-omics insights, artificial intelligence, and novel therapeutics for precision medicine
  Tao Li, Kaili Chen, Yiting Sun, Linqi Zhang
  Frontiers in Genetics.2026;[Epub]     CrossRef
• Nobiletin Ameliorated the Development of Diabetic Kidney Disease via Modulating Ferroptosis and Epithelial–Mesenchymal Transition Involving Gut–Kidney Axis
  Tingting Zhao, Chuyun Zhao, Qian Xiang, Xi Zhang, Kin-Fong Hong, Peiyu Liu, Zhongyan Sun, Yadi Liu, Ruiting Huang, Yiran Li, Hio-Fai Cheong, Yuwei Wu, Yingqiu Mo, Yiduo Xu, Yingxi Zhao, Qiruo Huang, Ying Xie, Youhua Xu
  The American Journal of Chinese Medicine.2026; : 1.     CrossRef
• Special Issue “Molecular Therapeutics for Diabetes and Related Complications”
  Kota V. Ramana
  International Journal of Molecular Sciences.2025; 26(12): 5585.     CrossRef
• Targeting ion channel networks in diabetic kidney disease: from molecular crosstalk to precision therapeutics and clinical innovation
  Wenfeng Wang, Bi Ke, Chen Wang, Xiaojing Xiong, Xiuyuan Feng, Hua Yan
  Frontiers in Medicine.2025;[Epub]     CrossRef
• SGLT2 Inhibitors and GLP-1 Receptor Agonists in Cardiovascular–Kidney–Metabolic Syndrome
  Aryan Gajjar, Arvind Kumar Raju, Amani Gajjar, Mythili Menon, Syed Asfand Yar Shah, Sourbha Dani, Andrew Weinberg
  Biomedicines.2025; 13(8): 1924.     CrossRef
• Comparative analysis on renal and cardiovascular outcomes of antidiabetic treatment in chronic kidney disease patients—A systematic review and network meta‐analysis
  Peter Bramlage, Anjaly Vijayan, Treesa P. Varghese, Deepthy Melepurakkal Sadanandan, Stefanie Lanzinger, Carmen Ferrero Rodriguez
  Diabetes, Obesity and Metabolism.2025; 27(11): 6254.     CrossRef
• Type 2 Diabetes and the Multifaceted Gut-X Axes
  Hezixian Guo, Liyi Pan, Qiuyi Wu, Linhao Wang, Zongjian Huang, Jie Wang, Li Wang, Xiang Fang, Sashuang Dong, Yanhua Zhu, Zhenlin Liao
  Nutrients.2025; 17(16): 2708.     CrossRef
• Nutriomics and artificial intelligence nutrition obesity cohort (NAINOC): a design paper for a prospective cohort for nutrition and obesity research
  Minyoung Lee, Sungha Park, Soo-Hyun Park, Ho-Young Park, Yu Ra Lee, Min-Sun Kim, Miso Nam, Jangho Lee, Hyein Seo, Yong-ho Lee, Chan Joo Lee, Jae-Ho Park, Hye Hyun Yoo, Hyun-Jin Kim, Kyong-Oh Shin, Yoshikazu Uchida, Kyungho Park
  Clinical Hypertension.2025;[Epub]     CrossRef
• Microvascular Outcomes of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Type 2 Diabetes: A Systematic Review of Retinopathy and Nephropathy Evidence
  Atia Arif, Sanu Lama, Bhavna Singla, Shivam Singla, Sunita Kumawat, Anusha Tharwani, Muhammad Usman, Hamna Khalid, Venkata Madusudana Rao Kanukollu, Osatohanmwen Ekomwereren, Shabir Khan
  Cureus.2025;[Epub]     CrossRef
• Integrating UHPLC-QE-MS and Bioinformatics with Experimental Validation Reveals MAPK/FOS-Mediated Podocyte Apoptosis as the Key Mechanism of Alpiniae oxyphyllae and Saposhnikovia divaricata in Treating Diabetic Kidney Disease
  Xian Wang, Lin Zhang, Rongxin Tang, Wenlong Zhang, Yiqiang Xie, Kai Li
  Pharmaceuticals.2025; 18(10): 1449.     CrossRef
• Renoprotective effect of dulaglutide in L-NAME-induced hypertensive nephropathy in rats: insight into the roles of PPAR-gamma and VEGF
  Nermeen Bastawy, Aliaa E. M. K. El-Mosallamy, Rabab Ahmed Rasheed, A. S. Sadek, R. T. Khattab, Esraa Ali, Randa A. Zaghloul, Wael B. A. Ghaly, Amy F. Boushra
  Hypertension Research.2025;[Epub]     CrossRef
• GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity
  Mark E. Cooper, Daniël H. van Raalte
  Journal of Clinical Investigation.2025;[Epub]     CrossRef
• Short-Term Laboratory Outcomes of SGLT2 Inhibitor Use in Type 2 Diabetic Patients: A Retrospective Analysis
  Hamood AlSudais, Turky AlSulaiman, Badi A. Alotaibi, Abdulrahman Alshalani, Abdulaziz M. Almuqrin, Rehab B. Albakr, Jehad A. Aldali
  Journal of Clinical Medicine.2025; 14(22): 7985.     CrossRef
• Chronic cardiorenal syndrome: cardio-renal protective effect of SGLT2i
  Yixin Zhu, Chenxi Lv, Hanqi Yang, Qian Lu, XuChen Wang, Yueqi Zhang, Maojuan Guo, Bo Yang
  Renal Failure.2025;[Epub]     CrossRef
• FGF4-FGFR1 signaling promotes podocyte survival and glomerular function to ameliorate diabetic kidney disease in male mice
  Jie Zhou, Shuxin Wang, Jiaxin Lou, Beibin Pan, Min Zhao, Qian Li, Jing Zhou, Yali Du, Shuodan Ding, Meiling Yu, Jingjing Zhou, Xinwei Chen, Lingwei Jin, Xinyi Wang, Yepeng Hu, Zhe Wang, Xiaokun Li, Chao Zheng, Jian Sun, Zhifeng Huang
  Nature Communications.2025;[Epub]     CrossRef
• Food‐Herb Dual‐Function in Astragali Radix‐Poria‐Rheum: Network Pharmacology and Database Mining for Diabetic Kidney Disease Mechanisms Exploration
  Meizi Wang, Weizhong Li, Qiong Cheng, Jiayu Sun, Cheng Cheng, Nana Wang, Ping Zhou, Min Zha, Yufeng Yang
  Food Science & Nutrition.2025;[Epub]     CrossRef
• Sodium‐glucose cotransporter 2 inhibitor ameliorates thiazolidinedione‐induced fluid retention through vascular leakage reduction in white adipose tissue
  Ji Yoon Kim, Hye‐Min Jang, Hye‐Jin Lee, Ah Hyeon Lee, Dong‐Hoon Kim, Sin Gon Kim, Nam Hoon Kim
  Diabetes, Obesity and Metabolism.2025;[Epub]     CrossRef
• Інгібітори натрій-глюкозного котранспортера 2-го типу в контексті кардіоренально-метаболічної коморбідності. Частина 1: основи патофізіології та ключові клінічні дослідження
  Vira V. Zlatkina, Andriy O. Nesen, Nadiia V. Demikhova
  Ukrainian Journal of Nephrology and Dialysis.2025; (4(88)): 88.     CrossRef
• GLP-1 Receptor Agonists and Blood Pressure: A State-of-the-Art Review of Mechanisms, Evidence, and Clinical Implications
  Areesha Moiz, Tetiana Zolotarova, Kristian B Filion, Mark J Eisenberg
  American Journal of Hypertension.2025;[Epub]     CrossRef

Citations

Citations to this article as recorded by  

• Semaglutide beyond weight loss: Mechanistic insights and functional paradoxes from the SEMALEAN study
  Shambo S. Samajdar, Shashank Joshi
  Diabetes, Obesity and Metabolism.2026; 28(1): 779.     CrossRef
• An expert narrative review on the brain-kidney axis in diabetic kidney disease: Mechanisms and therapeutic insights
  Zongrui Zhang, Rangzi Yi, Shihong Xiong, Yushu Zhang, Xuebin Cao, Wenqi Zhen, Yang Yang, Na Gong
  Diabetes Research and Clinical Practice.2026; 233: 113055.     CrossRef
• Impaired Brain Incretin and Gut Hormone Expression in Human Alcohol-Related Brain Damage: Opportunities for Therapeutic Targeting
  Suzanne M. de la Monte, Ming Tong, Rolf I. Carlson, Greg Sutherland
  Biomolecules.2026; 16(1): 99.     CrossRef
• Plasma GLP-1 (Glucagon-like Peptide-1) Depletion Is Correlated with Dysregulation of Adipocytokine in Type 2 Diabetic Patients With or Without Metabolic-Associated Fatty Liver Disease (MAFLD): A Cross-Sectional Study Related to Gender-Sex Disparities
  Zoubiri Houda, Saiah Wassila, Otmane Amel, Saidi Hamza, Makrelouf Mohamed, Aitabderrhmane Samir, Haddam Ali El Mahdi, Koceir Elhadj-Ahmed
  International Journal of Molecular Sciences.2026; 27(3): 1218.     CrossRef
• The Enterolimbic Axis: Gut-Brain Affective Circuits at the Crossroad of Metabolism, Emotion, and Behavior
  Antonio Gasbarrini, Francesca Sofia Galli, Gianluca Ianiro, Francesca Ponziani, Emanuele Rinninella
  American Journal of Gastroenterology.2026;[Epub]     CrossRef
• Hijacked Brain in Modern Obesity: Cue, Habit, Addiction, Emotion, and Restraint as Targets for Personalized Digital Therapy and Electroceuticals
  Taesung Lee, Seeun Park, Seokhyun Lee, Areum Hwangbo, HanGyeol Bae, Yumin Lee, Hyung Jin Choi
  Journal of Obesity & Metabolic Syndrome.2025; 34(3): 196.     CrossRef
• Long-Term Efficacy Trajectories of GLP-1 Receptor Agonists: A Systematic Review and Network Meta-Analysis
  Zixuan Li, Zhoubo Han, Rong Sun, Xiuping Xuan, Chenghu Huang
  Diabetes, Metabolic Syndrome and Obesity.2025; Volume 18: 3611.     CrossRef
• The LEPR gene: A multifaceted regulator of energy homeostasis, obesity pathogenesis, and metabolic health
  Isar Sharma, Nishutosh, Kritika Bakshi, Ritu Mahajan, Nisha Kapoor
  Human Gene.2025; 46: 201486.     CrossRef
• Glucagon-Like Peptide-1 Receptor Agonists Are Promising for the Treatment of Brain Diseases: an Outlook from the Perspective of Integrative Physiology
  N. V. Gulyaeva
  Journal of Evolutionary Biochemistry and Physiology.2025; 61(5): 1326.     CrossRef
• Beyond Weight Loss: GLP-1 Usage and Appetite Regulation in the Context of Eating Disorders and Psychosocial Processes
  Isabel Krug, An Binh Dang, Jade Portingale, Yakun Li, Ying Qing Won
  Nutrients.2025; 17(23): 3735.     CrossRef
• A personalized, evidence-based approach to obesity therapy using clinical algorithms: semaglutide or tirzepatide
  E. A. Troshina, M. B. Antsiferov, A. S. Ametov, G. R. Galstyan, T. N. Markova, T. I. Romantsova, N. V. Mazurina, O. M. Koteshkova
  Problems of Endocrinology.2025; 71(5): 19.     CrossRef
• Tirzepatide and Obesity: A Narrative Review
  Arya Singh, Rahnuma Ahmad, Kona Chowdhury, Mahendra Narwaria, Mainul Haque
  Advances in Human Biology.2025;[Epub]     CrossRef

Citations

Citations to this article as recorded by  

• Implications of Glucagon-like Peptide-1 Receptor Agonists on Thyroid Function and Thyroid Nodules: A Drug Target Mendelian Randomization and Cohort Study
  Zhijun Zhang, Jingyun Yang, Ling Gao
  Endocrine Practice.2026; 32(1): 60.     CrossRef
• Assessment of thyroid cancer risk associated with glucagon‐like peptide 1 receptor agonist use
  Tina Vilsbøll, Michael Stellfeld, Vanita R. Aroda, Sune Dandanell, Jens‐Peter David, Ceyda T. P. Kristiansen, Søren Rasmussen, Fiona L. Roberts, Laszlo Hegedüs
  Diabetes, Obesity and Metabolism.2026; 28(2): 1499.     CrossRef
• Safety and Tolerability of Glucagon-Like Peptide-1 Receptor Agonists: A State-of-the-Art Narrative Review
  Setor K. Kunutsor, Samuel Seidu
  Drugs.2026; 86(1): 11.     CrossRef
• Glucagon-like Peptide-1 Receptor Agonist Use and Pancreatic Cancer Risk in Patients with Chronic Pancreatitis
  Sarina Ailawadi, Jennifer E. Murphy, Michael H. Storandt, Amit Mahipal
  Cancers.2026; 18(2): 179.     CrossRef
• GLP‐1 receptor agonists and the risk for cancer: A meta‐analysis of randomized controlled trials
  Giovanni Antonio Silverii, Christian Marinelli, Costanza Bettarini, Gloria Giovanna Del Vescovo, Matteo Monami, Edoardo Mannucci
  Diabetes, Obesity and Metabolism.2025; 27(8): 4454.     CrossRef
• Evaluating Thyroid Cancer Risk in Glucagon-like Peptide-1 Analog Users With Thyroid Nodules
  Sanjana Balachandra, Rohma Syed, Zhixing Song, Julia Kasmirski, Andrea Gillis, Jessica Fazendin, Brenessa Lindeman, Herbert Chen
  Journal of Surgical Research.2025; 312: 104.     CrossRef
• Exploring the Side Effects of GLP-1 Receptor Agonist: To Ensure Its Optimal Positioning
  Jung A Kim, Hye Jin Yoo
  Diabetes & Metabolism Journal.2025; 49(4): 525.     CrossRef
• Association between Cancer and Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes: A Systematic Review of Retrospective Cohort Studies
  Hyun Jin Park, Si Yoon Lee
  Research in Clinical Pharmacy.2025; 3(1): 28.     CrossRef
• GLP-1 Receptor Agonists Initiation and Risk of Acute Pancreatitis and Pancreatic Cancer: A Real-World Comparative Study
  Omar Faour, Moheb Boktor, Hanford Yau, Mustafa Kinaan, Ishak A Mansi
  American Journal of Medicine Open.2025; 14: 100114.     CrossRef
• Semaglutide and weight management in the Arab countries: Focus on the United Arab Emirates
  Sabina Semiz
  Health Sciences Review.2025; 17: 100244.     CrossRef
• GLP-1 receptor agonists and cancer: current clinical evidence and translational opportunities for preclinical research
  Estefania Valencia-Rincón, Rajani Rai, Vishal Chandra, Elizabeth A. Wellberg
  Journal of Clinical Investigation.2025;[Epub]     CrossRef
• GLP-1 Receptor Agonists in Solid Tumour Therapy: Exploring Their Anticancer Potential and Underlying Molecular Pathways
  Daniela Lucente, Stefania Bellino, Anna La Salvia
  Genes.2025; 16(11): 1352.     CrossRef
• Insulin resistance and metabolic dysfunction in thyroid nodules and differentiated thyroid cancer
  Stefano Iuliano, Maria Mirabelli, Stefania Giuliano, Antonio Brunetti
  Current Opinion in Oncology.2025;[Epub]     CrossRef
• Bridging Efficacy and Adherence in Glucagon-Like Peptide-1 Receptor Agonist Therapy: The Emerging Role of Oral Agents
  Sherry Yun Wang, Ryan Stofer, Hao Wang, Gregory A. Brent, Lu Shi, Yu Cai, Moom Roosan, Tannaz Moin
  Diabetes & Metabolism Journal.2025; 49(6): 1331.     CrossRef
• Joint Society Statement From the Society for Endocrinology (SfE), the British Thyroid Association (BTA) and the British Association of Endocrine and Thyroid Surgeons (BAETS) Regarding the Association of GLP‐1 Agonists and Thyroid Cancer
  Emma Watts, Jonathan Wadsley, Neil Sharma, Kristien Boelaert
  Clinical Endocrinology.2025;[Epub]     CrossRef

The glucagon-like peptide-1 receptor agonists (GLP-1RAs) were recommended as a monotherapy or combination therapy with oral hypoglycemic agents or basal insulin in the position statement of the Korean Diabetes Association 2017 for pharmacological therapy. Many randomized clinical trials and systematic reviews report that GLP-1RAs have considerable glucose-lowering effect and lead to weight reduction and low risk of hypoglycemia when used as a monotherapy or combination therapy. The cardiovascular safety of GLP-1RAs has been assessed in several randomized clinical trials and systematic reviews. The results of cardiovascular outcome trials of long-acting GLP-1RAs (liraglutide, semaglutide) demonstrated cardiovascular benefits in subjects with type 2 diabetes mellitus and a high risk of cardiovascular disease. The GLP-1RA may be a choice of therapy when weight control and avoidance of hypoglycemia are important, and patients with high risk of cardiovascular disease might also favor choosing GLP-1RA.

Citations

Citations to this article as recorded by  

• Anti-inflammatory effect of glucagon-like Peptide-1 receptor agonist on the neurosensory retina in an acute optic nerve injury rat model
  Yeon Woong Chung, Ji Young Lee, Hyun Hee Ju, Jin A. Choi
  European Journal of Pharmacology.2022; 933: 175269.     CrossRef
• Diabetes Risk Data Mining Method Based on Electronic Medical Record Analysis
  Yang Liu, Zhaoxiang Yu, Yunlong Yang, Zhihan Lv
  Journal of Healthcare Engineering.2021; 2021: 1.     CrossRef
• Paradigm Shift for the Treatment of Type 2 Diabetes Mellitus in Patients with Cardiovascular Disease: Cardiologist's Perspective
  Doo Soo Jeon
  Cardiovascular Prevention and Pharmacotherapy.2020; 2(1): 11.     CrossRef
• The Role of Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes in Asia
  Ju-Ming Lu
  Advances in Therapy.2019; 36(4): 798.     CrossRef
• A Review of Practical Issues on the Use of Glucagon-Like Peptide-1 Receptor Agonists for the Management of Type 2 Diabetes
  Irene Romera, Ana Cebrián-Cuenca, Fernando Álvarez-Guisasola, Fernando Gomez-Peralta, Jesús Reviriego
  Diabetes Therapy.2019; 10(1): 5.     CrossRef
• Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus: A Position Statement of the Korean Diabetes Association
  Hyun Jin Kim
  The Journal of Korean Diabetes.2018; 19(1): 35.     CrossRef

Type 2 diabetes mellitus (T2DM) is a multifactorial disease with a complex and progressive pathogenesis. The two primary mechanisms of T2DM pathogenesis are pancreatic β-cell dysfunction and insulin resistance. Pancreatic β-cell dysfunction is recognized to be a prerequisite for the development of T2DM. Therapeutic modalities that improve β-cell function are considered critical to T2DM management; however, blood glucose control remains a challenge for many patients due to suboptimal treatment efficacy and the progressive nature of T2DM. Incretin-based therapies are now the most frequently prescribed antidiabetic drugs in Korea. Incretin-based therapies are a favorable class of drugs due to their ability to reduce blood glucose by targeting the incretin hormone system and, most notably, their potential to improve pancreatic β-cell function. This review outlines the current understanding of the incretin hormone system in T2DM and summarizes recent updates on the effect of incretin-based therapies on β-cell function and β-cell mass in animals and humans.

Citations

Citations to this article as recorded by  

• The AMPK-SIRT1 Axis: Redefining type 2 diabetes mellitus management
  Mighty Kemelo, Phillip Moseki
  Results in Chemistry.2025; 14: 102139.     CrossRef
• Cyanidin-3-O-glucoside enhances GLP-1 secretion via PPARβ/δ-β-catenin-TCF-4 pathway in type 2 diabetes mellitus
  Xiang Ye, Wen Chen, Fujie Yan, Xiaodong Zheng, Pengcheng Tu
  npj Science of Food.2025;[Epub]     CrossRef
• Local Insulin for Local Needs? Insights into Retinal Insulin Signaling and RPE Metabolism
  Matilde Balbi, Alessandra Puddu, Andrea Amaroli, Davide Maggi, Isabella Panfoli, Silvia Ravera
  Biomolecules.2025; 15(11): 1570.     CrossRef
• Scars of oxidative stress: protein carbonylation and beta cell dysfunction in diabetes
  Ashley Ling, Katherine R. Schultz, Jefferson D. Knight, Colin T. Shearn, Sharon Baumel-Alterzon
  Frontiers in Endocrinology.2025;[Epub]     CrossRef
• GLP-1 Analogue-Loaded Glucose-Responsive Nanoparticles as Allies of Stem Cell Therapies for the Treatment of Type I Diabetes
  Joana Moreira Marques, Rute Nunes, Ana Margarida Carvalho, Helena Florindo, Domingos Ferreira, Bruno Sarmento
  ACS Pharmacology & Translational Science.2024; 7(5): 1650.     CrossRef
• Bisphenol a accelerates the glucolipotoxicity-induced dysfunction of rat insulinoma cell lines: An implication for a potential risk of environmental bisphenol a exposure for individuals susceptible to type 2 diabetes
  Chengmeng Huang, Xiaolin Chen, Zedong Ouyang, Lingxue Meng, Jian Liu, Qihua Pang, Ruifang Fan
  Toxicology in Vitro.2024; 99: 105866.     CrossRef
• Harnessing gut cells for functional insulin production: Strategies and challenges
  Kelvin Baafi, John C. March
  Biotechnology Notes.2023; 4: 7.     CrossRef
• Incretin and Pancreatic β-Cell Function in Patients with Type 2 Diabetes
  Chang Ho Ahn, Tae Jung Oh, Se Hee Min, Young Min Cho
  Endocrinology and Metabolism.2023; 38(1): 1.     CrossRef
• Weight loss maintenance with exercise and liraglutide improves glucose tolerance, glucagon response, and beta cell function
  Simon B. K. Jensen, Christian R. Juhl, Charlotte Janus, Julie R. Lundgren, Christoffer Martinussen, Christoffer Wiingaard, Cecilie Knudsen, Ruth Frikke‐Schmidt, Bente M. Stallknecht, Jens J. Holst, Sten Madsbad, Signe S. Torekov
  Obesity.2023; 31(4): 977.     CrossRef
• How do parasitic worms prevent diabetes? An exploration of their influence on macrophage and β-cell crosstalk
  Inah Camaya, Bronwyn O’Brien, Sheila Donnelly
  Frontiers in Endocrinology.2023;[Epub]     CrossRef
• An Imbalance of Pathophysiologic Factors in Late Postprandial Hypoglycemia Post Bariatric Surgery: A Narrative Review
  Marah Alsayed Hasan, Stanley Schwartz, Victoria McKenna, Richard Ing
  Obesity Surgery.2023; 33(9): 2927.     CrossRef
• Therapeutic Dilemma in Personalized Medicine
  Ehab S. EL Desoky
  Current Reviews in Clinical and Experimental Pharmacology.2022; 17(2): 94.     CrossRef
• Lessons from neonatal β-cell epigenomic for diabetes prevention and treatment
  Amar Abderrahmani, Cécile Jacovetti, Romano Regazzi
  Trends in Endocrinology & Metabolism.2022; 33(6): 378.     CrossRef
• Beneficial metabolic effects of recurrent periods of beta‐cell rest and stimulation using stable neuropeptide Y1 and glucagon‐like peptide‐1 receptor agonists
  Neil Tanday, Ryan A. Lafferty, Peter R. Flatt, Nigel Irwin
  Diabetes, Obesity and Metabolism.2022; 24(12): 2353.     CrossRef
• A Randomized Controlled Trial of R-Form Verapamil Added to Ongoing Metformin Therapy in Patients with Type 2 Diabetes
  Chih-Yuan Wang, Kuo-Chin Huang, Chia-Wen Lu, Chih-Hsun Chu, Chien-Ning Huang, Harn-Shen Chen, I-Te Lee, Jung-Fu Chen, Ching-Chu Chen, Chung-Sen Chen, Chang-Hsun Hsieh, Kai-Jen Tien, Hung-Yu Chien, Yu-Yao Huang, Jui-Pao Hsu, Guang-Tzuu Shane, Ai-Ching Chan
  The Journal of Clinical Endocrinology & Metabolism.2022; 107(10): e4063.     CrossRef
• Exenatide, Metformin, or Both for Prediabetes in PCOS: A Randomized, Open-label, Parallel-group Controlled Study
  Tao Tao, Yi Zhang, Yu-Chen Zhu, Jia-Rong Fu, Yu-Ying Wang, Jie Cai, Jing-Yu Ma, Yu Xu, Yi-Ning Gao, Yun Sun, WuQiang Fan, Wei Liu
  The Journal of Clinical Endocrinology & Metabolism.2021; 106(3): e1420.     CrossRef
• The utility of assessing C-peptide in patients with insulin-treated type 2 diabetes: a cross-sectional study
  Tuccinardi Dario, Giorgino Riccardo, Pieralice Silvia, Watanabe Mikiko, Maggi Daria, Palermo Andrea, Defeudis Giuseppe, Fioriti Elvira, Pozzilli Paolo, Manfrini Silvia
  Acta Diabetologica.2021; 58(4): 411.     CrossRef
• Type 2 diabetes: evidence-based medicine approach to glucose-lowering therapy
  E. V. Biryukova, I. A. Morozova, S. V. Rodionova
  Meditsinskiy sovet = Medical Council.2021; (21): 160.     CrossRef
• Emerging Role of Caveolin-1 in GLP-1 Action
  Alessandra Puddu, Davide Maggi
  Frontiers in Endocrinology.2021;[Epub]     CrossRef
• Improvements in HOMA indices and pancreatic endocrinal tissues in type 2-diabetic rats by DPP-4 inhibition and antioxidant potential of an ethanol fruit extract of Withania coagulans
  Heera Ram, Pramod Kumar, Ashok Purohit, Priya Kashyap, Suresh Kumar, Shivani Kumar, Garima Singh, Abdulaziz A. Alqarawi, Abeer Hashem, Elsayed Fathi Abd-Allah, Al-Bandari Fahad Al-Arjani, Bhim Pratap Singh
  Nutrition & Metabolism.2021;[Epub]     CrossRef
• Chop / Ddit3 depletion in β cells alleviates ER stress and corrects hepatic steatosis in mice
  Jing Yong, Vishal S. Parekh, Shannon M. Reilly, Jonamani Nayak, Zhouji Chen, Cynthia Lebeaupin, Insook Jang, Jiangwei Zhang, Thazha P. Prakash, Hong Sun, Sue Murray, Shuling Guo, Julio E. Ayala, Leslie S. Satin, Alan R. Saltiel, Randal J. Kaufman
  Science Translational Medicine.2021;[Epub]     CrossRef
• Assessment of Insulin Secretion and Insulin Resistance in Human
  So Young Park, Jean-François Gautier, Suk Chon
  Diabetes & Metabolism Journal.2021; 45(5): 641.     CrossRef
• Targeted pharmacological therapy restores β-cell function for diabetes remission
  Stephan Sachs, Aimée Bastidas-Ponce, Sophie Tritschler, Mostafa Bakhti, Anika Böttcher, Miguel A. Sánchez-Garrido, Marta Tarquis-Medina, Maximilian Kleinert, Katrin Fischer, Sigrid Jall, Alexandra Harger, Erik Bader, Sara Roscioni, Siegfried Ussar, Annett
  Nature Metabolism.2020; 2(2): 192.     CrossRef
• The Relationship Between Timing of Initiation on a Glucagon-like Peptide-1 Receptor Agonist and Glycosylated Hemoglobin Values Among Patients With Type 2 Diabetes
  Kristina S. Boye, Reema Mody, Maureen J. Lage, Raleigh E. Malik
  Clinical Therapeutics.2020; 42(9): 1812.     CrossRef
• Short-term renal and metabolic effects of low dose vildagliptin treatment added-on insulin therapy in non-proteinuric patients with type 2 diabetes: open-label randomized prospective study
  Valentina K. Bayrasheva, Ivan Y. Pchelin, Vladimir A. Dobronravov, Alina Yu. Babenko, Svetlana G. Chefu, Ivan S. Shatalov, Volha N. Vasilkova, Natalia V. Hudiakova, Alexandra N. Ivanova, Pavel A. Andoskin, Elena N. Grineva
  Archives of Endocrinology and Metabolism.2020;[Epub]     CrossRef
• A Phenotypic Screen Identifies Calcium Overload as a Key Mechanism of β-Cell Glucolipotoxicity
  Jennifer Vogel, Jianning Yin, Liansheng Su, Sharon X. Wang, Richard Zessis, Sena Fowler, Chun-Hao Chiu, Aaron C. Wilson, Amy Chen, Frederic Zecri, Gordon Turner, Thomas M. Smith, Brian DeChristopher, Heming Xing, Deborah M. Rothman, Xinming Cai, Alina Ber
  Diabetes.2020; 69(5): 1032.     CrossRef
• Neuropeptide 26RFa (QRFP) is a key regulator of glucose homeostasis and its activity is markedly altered in obese/hyperglycemic mice
  Gaëtan Prévost, Arnaud Arabo, Marie-Anne Le Solliec, Justine Bons, Marie Picot, Julie Maucotel, Hind Berrahmoune, Mouna El Mehdi, Saloua Cherifi, Alexandre Benani, Emmanuelle Nédélec, Moïse Coëffier, Jérôme Leprince, Anneli Nordqvist, Valéry Brunel, Pierr
  American Journal of Physiology-Endocrinology and Metabolism.2019; 317(1): E147.     CrossRef
• Gastrin analogue administration adds no significant glycaemic benefit to a glucagon‐like peptide‐1 receptor agonist acutely or after washout of both analogues
  Krister Bokvist, Ying Ding, William H. Landschulz, Vikram Sinha, Aleksandra Pastrak, Ruth M. Belin
  Diabetes, Obesity and Metabolism.2019; 21(7): 1606.     CrossRef
• Effects of boschnaloside from Boschniakia rossica on dysglycemia and islet dysfunction in severely diabetic mice through modulating the action of glucagon-like peptide-1
  Lie-Chwen Lin, Lin-Chien Lee, Cheng Huang, Chiung-Tong Chen, Jen-Shin Song, Young-Ji Shiao, Hui-Kang Liu
  Phytomedicine.2019; 62: 152946.     CrossRef
• The future of new drugs for diabetes management
  Clifford J. Bailey, Caroline Day
  Diabetes Research and Clinical Practice.2019; 155: 107785.     CrossRef
• Compact fluidic system for functional assessment of pancreatic islets
  Takeshi Hori, Kei Yamane, Takayuki Anazawa, Osamu Kurosawa, Hiroo Iwata
  Biomedical Microdevices.2019;[Epub]     CrossRef
• Pharmacokinetics of Exenatide in nonhuman primates following its administration in the form of sustained-release PT320 and Bydureon
  Yazhou Li, Kelli L. Vaughan, David Tweedie, Jin Jung, Hee Kyung Kim, Ho-Il Choi, Dong Seok Kim, Julie A. Mattison, Nigel H. Greig
  Scientific Reports.2019;[Epub]     CrossRef
• Pharmacokinetics and efficacy of PT302, a sustained-release Exenatide formulation, in a murine model of mild traumatic brain injury
  Miaad Bader, Yazhou Li, Daniela Lecca, Vardit Rubovitch, David Tweedie, Elliot Glotfelty, Lital Rachmany, Hee Kyung Kim, Ho-Il Choi, Barry J. Hoffer, Chaim G. Pick, Nigel H. Greig, Dong Seok Kim
  Neurobiology of Disease.2019; 124: 439.     CrossRef
• Novel dual incretin agonist peptide with antidiabetic and neuroprotective potential
  N.M. Pathak, V. Pathak, V.A. Gault, S. McClean, N. Irwin, P.R. Flatt
  Biochemical Pharmacology.2018; 155: 264.     CrossRef
• Human EndoC-βH1 β-cells form pseudoislets with improved glucose sensitivity and enhanced GLP-1 signaling in the presence of islet-derived endothelial cells
  Michael G. Spelios, Lauren A. Afinowicz, Regine C. Tipon, Eitan M. Akirav
  American Journal of Physiology-Endocrinology and Metabolism.2018; 314(5): E512.     CrossRef
• Vildagliptin: ten years in the service for type 2 diabetes mellitus patients. The journey of discovery, innovation and success in clinical practice
  Tatiana Yu. Demidova
  Problems of Endocrinology.2018; 64(5): 336.     CrossRef
• Thromboxane-Dependent Platelet Activation in Obese Subjects with Prediabetes or Early Type 2 Diabetes: Effects of Liraglutide- or Lifestyle Changes-Induced Weight Loss
  Paola Simeone, Rossella Liani, Romina Tripaldi, Augusto Di Castelnuovo, Maria Teresa Guagnano, Armando Tartaro, Riccardo C. Bonadonna, Virginia Federico, Francesco Cipollone, Agostino Consoli, Francesca Santilli
  Nutrients.2018; 10(12): 1872.     CrossRef
• Nutrient regulation of β-cell function: what do islet cell/animal studies tell us?
  R Carlessi, K N Keane, C Mamotte, P Newsholme
  European Journal of Clinical Nutrition.2017; 71(7): 890.     CrossRef
• Effectiveness and safety of exenatide in Korean patients with type 2 diabetes inadequately controlled with oral hypoglycemic agents: an observational study in a real clinical practice
  You-Cheol Hwang, Ari Kim, Euna Jo, Yeoree Yang, Jae-Hyoung Cho, Byung-Wan Lee
  BMC Endocrine Disorders.2017;[Epub]     CrossRef
• Efficacy and safety of adding evogliptin versus sitagliptin for metformin‐treated patients with type 2 diabetes: A 24‐week randomized, controlled trial with open label extension
  Sang‐Mo Hong, Cheol‐Young Park, Dong‐Min Hwang, Kyung Ah Han, Chang Beom Lee, Choon Hee Chung, Kun‐Ho Yoon, Ji‐Oh Mok, Kyong Soo Park, Sung‐Woo Park
  Diabetes, Obesity and Metabolism.2017; 19(5): 654.     CrossRef
• The effects of vildagliptin compared with metformin on vascular endothelial function and metabolic parameters: a randomized, controlled trial (Sapporo Athero-Incretin Study 3)
  Naoyuki Kitao, Hideaki Miyoshi, Tomoo Furumoto, Kota Ono, Hiroshi Nomoto, Aika Miya, Chiho Yamamoto, Atsushi Inoue, Kenichi Tsuchida, Naoki Manda, Yoshio Kurihara, Shin Aoki, Akinobu Nakamura, Tatsuya Atsumi
  Cardiovascular Diabetology.2017;[Epub]     CrossRef
• Recent Advances in Effect‐directed Enzyme Assays based on Thin‐layer Chromatography
  Sarah Bräm, Evelyn Wolfram
  Phytochemical Analysis.2017; 28(2): 74.     CrossRef
• Efficacy and safety of gemigliptin, a dipeptidyl peptidase‐4 inhibitor, in patients with type 2 diabetes mellitus inadequately controlled with combination treatment of metformin and sulphonylurea: a 24‐week, multicentre, randomized, double‐blind, placebo‐
  Chang Ho Ahn, Kyung Ah Han, Jae Myung Yu, Joo Young Nam, Kyu Jeung Ahn, Tae Keun Oh, Hyoung Woo Lee, Dae Ho Lee, Jaetaek Kim, Choon Hee Chung, Tae Sun Park, Byung Joon Kim, Seok Won Park, Hyeong Kyu Park, Kwang Jae Lee, Sang‐Wook Kim, Jeong Hyun Park, Kwa
  Diabetes, Obesity and Metabolism.2017; 19(5): 635.     CrossRef
• Antihyperglycemic agent therapy for adult patients with type 2 diabetes mellitus 2017: a position statement of the Korean Diabetes Association
  Seung-Hyun Ko, Kyu-Yeon Hur, Sang Youl Rhee, Nan-Hee Kim, Min Kyong Moon, Seok-O Park, Byung-Wan Lee, Hyun Jin Kim, Kyung Mook Choi, Jin Hwa Kim
  The Korean Journal of Internal Medicine.2017; 32(6): 947.     CrossRef
• Antihyperglycemic Agent Therapy for Adult Patients with Type 2 Diabetes Mellitus 2017: A Position Statement of the Korean Diabetes Association
  Seung-Hyun Ko, Kyu-Yeon Hur, Sang Youl Rhee, Nan-Hee Kim, Min Kyong Moon, Seok-O Park, Byung-Wan Lee, Hyun Jin Kim, Kyung Mook Choi, Jin Hwa Kim
  Diabetes & Metabolism Journal.2017; 41(5): 337.     CrossRef
• DPP-4 inhibitors in diabetic complications: role of DPP-4 beyond glucose control
  Eun Ju Bae
  Archives of Pharmacal Research.2016; 39(8): 1114.     CrossRef
• Liraglutide Enhances the Efficacy of Human Mesenchymal Stem Cells in Preserving Islet ß-cell Function in Severe Non-obese Diabetic Mice
  Li-rong Li, Jing Lu, Xiao-lei Jia, Hui Hui, Jie Zhang, Ying Liu, Wei-juan Cui, Qian-yue Xu, Da-long Zhu
  Molecular Medicine.2016; 22(1): 800.     CrossRef

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) reduce glycosylated hemoglobin (HbA1c, 0.5% to 1.0%), and are associated with moderate weight loss and a relatively low risk of hypoglycemia. There are differences between Asian and non-Asian populations. We reviewed available data on GLP-1RAs, focusing on Korean patients, to better understand their risk/benefit profile and help inform local clinical practice. Control of postprandial hyperglycemia is important in Asians in whom the prevalence of post-challenge hyperglycemia is higher (vs. non-Asians). The weight lowering effects of GLP-1RAs are becoming more salient as the prevalence of overweight and obesity among Korean patients increases. The higher rate of gastrointestinal adverse events amongst Asian patients in clinical trials may be caused by higher drug exposure due to the lower body mass index of the participants (vs. non-Asian studies). Data on the durability of weight loss, clinically important health outcomes, safety and optimal dosing in Korean patients are lacking. Use of GLP-1RAs is appropriate in several patient groups, including patients whose HbA1c is uncontrolled, especially if this is due to postprandial glucose excursions and patients who are overweight or obese due to dietary problems (e.g., appetite control). The potential for gastrointestinal adverse events should be explained to patients at treatment initiation to facilitate the promotion of better compliance.

Citations

Citations to this article as recorded by  

• Safety and Effectiveness of Dulaglutide in the Treatment of Type 2 Diabetes Mellitus: A Korean Real-World Post-Marketing Study
  Jeonghee Han, Woo Je Lee, Kyu Yeon Hur, Jae Hyoung Cho, Byung Wan Lee, Cheol-Young Park
  Diabetes & Metabolism Journal.2024; 48(3): 418.     CrossRef
• Tolerability and Effectiveness of Switching to Dulaglutide in Patients With Type 2 Diabetes Inadequately Controlled With Insulin Therapy
  Youngsook Kim, Ji Hye Huh, Minyoung Lee, Eun Seok Kang, Bong-Soo Cha, Byung-Wan Lee
  Frontiers in Endocrinology.2022;[Epub]     CrossRef
• Antihyperglycemic Agent Therapy for Adult Patients with Type 2 Diabetes Mellitus 2017: A Position Statement of the Korean Diabetes Association
  Seung-Hyun Ko, Kyu-Yeon Hur, Sang Youl Rhee, Nan-Hee Kim, Min Kyong Moon, Seok-O Park, Byung-Wan Lee, Hyun Jin Kim, Kyung Mook Choi, Jin Hwa Kim
  Diabetes & Metabolism Journal.2017; 41(5): 337.     CrossRef
• Antihyperglycemic agent therapy for adult patients with type 2 diabetes mellitus 2017: a position statement of the Korean Diabetes Association
  Seung-Hyun Ko, Kyu-Yeon Hur, Sang Youl Rhee, Nan-Hee Kim, Min Kyong Moon, Seok-O Park, Byung-Wan Lee, Hyun Jin Kim, Kyung Mook Choi, Jin Hwa Kim
  The Korean Journal of Internal Medicine.2017; 32(6): 947.     CrossRef